Submit Manuscript  

Article Details

The Study of Marketed and Experimental Formulation Approaches Enabling Site-specific Delivery of Mesalamine in Patients with Inflammatory Bowel Disease

[ Vol. 8 , Issue. 1 ]


Irina Kadiyala and Dylan Jacobs   Pages 3 - 11 ( 9 )


This patent review focuses exclusively on the oral delivery of mesalamine (5-ASA) and excludes oral mesalamine pro-drug and rectal delivery formulations. The formulation strategies of marketed formulations (Apriso®, Asacol®, Lialda® and Pentasa®) and non-marketed formulations are reviewed and explained by decoding formulation specifics that enable the site specific delivery for the treatment of inflammatory bowel disease.


Apriso, asacol, asacol HD, 5-ASA, Crohn’s disease and ulcerative colitis, inflammatory bowel disease, lialda, mesalamine, oral delivery, pentasa.


Vertex Pharmaceuticals Incorporated, Department of Formulation Development, 130 Waverly St., Cambridge, MA 02139-4242.

Read Full-Text article